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A non-randomised controlled pilot study of clinical pharmacist
collaborative intervention for community dwelling patients
with COPD
Vicki Hunt1, Dave Anderson2, Richard Lowrie3, Colette Montgomery Sardar 3, Susan Ballantyne4, Graeme Bryson5, John Kyle6 and
Peter Hanlon6
UK, home-based patients with COPD receive specialist care from respiratory physicians, nurses, and general practitioners (GPs), but
increasing complexity of therapeutic options and a GP/Nurse workforce crisis suggests merit in testing the role of home visits by a
clinical pharmacist. We conducted a non-randomised intervention study with a contemporaneous comparator group, in Glasgow
(Scotland). A clinical pharmacist (working closely with a consultant respiratory physician) visited patients with COPD living at home,
assessing respiratory and other co-morbid conditions, and medicines then, with patient approval, agreed treatment modiﬁcations
with a consultant physician. Comparator group-patients were drawn from another hospital out-patient clinic. Main outcomes were
exacerbations during 4-months of follow-up and respiratory hospitalisations (number and duration) after 1 year. In the intervention
group, 86 patients received a median of three home visits; 87 received usual care (UC). At baseline, patients in the intervention
group were similar to those in UC in terms of respiratory hospitalisations although slightly younger, more likely to receive speciﬁc
maintenance antibiotics/Prednisolone and to have had exacerbations. Sixty-two (72.1%) of the intervention group received dose
changes; 45 (52.3%) had medicines stopped/started and 21 (24.4%) received an expedited review at the specialist respiratory
consultant clinic; 46 (53.5%) were referred to other healthcare services. Over one-third were referred for bone scans and 11%
received additional investigations. At follow-up, 54 (63.5%) of intervention group participants had an exacerbation compared with
75 (86.2%) in the UC group (p= 0.001); fewer had respiratory hospitalisations (39 (45.3%) vs. 66 (76.7%); p < 0.001). Hospitalisations
were shorter in the intervention group. Pharmacist-consultant care for community dwelling patients with COPD, changed clinical
management and improved outcomes. A randomised controlled trial would establish causality.
npj Primary Care Respiratory Medicine  (2018) 28:38 ; doi:10.1038/s41533-018-0105-7
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a treatable
disease characterised by progressive airﬂow obstruction in
response to noxious particles or gases in the airways and lung,
and is the fourth leading cause of death worldwide.1 Smoking is
the predominant causative factor, with other exposures (e.g.,
occupational) also contributing, and COPD prevalence is projected
to increase.2,3 Advancing disease is characterised by recurrent
exacerbations (acute worsening of symptoms requiring additional
therapy), which often require hospital admission.2 Co-morbidity is
common and impacts negatively on quality of life and mortality.4
The economic burden of COPD is considerable, estimated at €38.6
billion per year (56% of the cost of respiratory disease) in the
European Union alone with a signiﬁcant proportion resulting from
unscheduled healthcare use resulting from exacerbations.5 COPD
admissions follow a socioeconomic gradient with higher rates in
patients living in poor areas.6 Optimal pharmacological treatment
including rapid treatment of exacerbations, can improve symp-
toms, reduce exacerbation frequency, and improve exercise
tolerance2,7 while poor medication adherence8 and suboptimal
inhaler technique negatively impact outcomes.2,9–11 The associa-
tion between poor medication adherence, and morbidity and
mortality in COPD, together with the preventable nature of some
exacerbations through tailored use of medicines,12,13 suggests a
potential role for pharmacists. Community Pharmacists and clinical
pharmacists working in hospitals, by improving adherence,
inhalation technique, and encouraging smoking cessation, may
decrease exacerbation rates.14–18 Review and modiﬁcation of
medicines for COPD and other morbidities by pharmacists has not
been tested, as far as we are aware.
In the UK, backed by strategic policy and a shortage of general
practitioners (GPs) and Nurses, Primary Care-based clinical
pharmacists work in general practices to support prescribing.19,20
Since the ﬁrst study of clinical pharmacists reviewing elderly
patients with multiple morbidities receiving polypharmacy in
Glasgow general practices in 1997,21,22 research has informed
expanded roles to include patients with heart failure and
multimorbidities23 and on prescribing through educational out-
reach targeted at GPs and nurses in general practices.24 To our
knowledge, only one UK-based study from over 10 years ago,
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showed an out-patient pharmacist-led intervention focussing only
on COPD improved outcomes in COPD.15 A more recent UK study
using pre- and post-intervention comparison, targeted patients
with COPD presenting to community pharmacies. Pharmacists
delivered a multifaceted intervention including therapy optimisa-
tion, however, they did not access medical records or collaborate
with other members of the multidisciplinary team, which limited
the scope for introduction of changes. Adherence and quality of
life improved while GP visits declined following pharmacist advice.
The authors suggested the intervention may have been cost
effective.25 However, home visits by a clinical pharmacist to review
and change medicines for COPD and other co-morbid conditions,
working collaboratively with a consultant respiratory physician for
respiratory issues, remains untested, despite the growing disease
burden, and the potential for improvements in management.26
In Scotland, among patients with long-term conditions, rates of
non-attendance at general practices was highest (12%) among
people with COPD,27 and non-attendance was higher among
patients living in more socioeconomically deprived areas27
suggesting the need for complementary, additional models of
care at home for this group of patients. Non-attendance at general
practices is associated with increased mortality.28 Across the UK,
respiratory nurses treat patients at home following assessment in
a hospital respiratory unit,29 and domiciliary support from
specialist respiratory nurses may be provided following respiratory
hospitalisation, with patients receiving out-patient physician, and
physiotherapy follow-up in hospital-based clinics.30 However,
other than during visits to their GP, patients do not receive a
review of all of their conditions together despite the prevalence
and negative impact of co-morbidities in COPD.31
Recent calls for more community-based models of care to help
minimise unscheduled healthcare use and reduce costs32 raises
the question: can a general practice-based clinical pharmacist—
consultant physician pilot intervention improve outcomes in
patients with moderate or severe COPD, through home visits?
We aimed to evaluate the impact of pharmacist-consultant
respiratory physician intervention on exacerbations, and respira-
tory hospitalisations. The intervention involves a pharmacist
visiting patients with COPD in their homes to assess respiratory
symptoms and other co-morbid conditions then introduce
changes (improvements) in the management of respiratory and
other co-morbid conditions, following discussion with the
patient’s respiratory physician. Changes introduced by the
pharmacist included prescribing of medicines, monitoring, or
onward referral, e.g., for bone density measurement. Patients were
visited several times, and the pharmacist communicated all
changes to the patient’s GP. This paper examines ﬁndings, from
a non-randomised controlled pilot study.
RESULTS
Patient identiﬁcation and engagement
In the intervention group, 88 patients were asked to participate;
86 agreed and two declined. The pharmacist visited patients for
the ﬁrst time at home from 5th March 2015 to 16th February 2016.
The last follow-up visit occurred on 31st March 2016. Baseline data
on exacerbations (acute prescribing of antibiotics or oral steroids)
were collected in the 4-month period leading up to the date of
ﬁrst consultation for each of the 86 patients who received a ﬁrst
visit and follow-up data on exacerbations were collected in the 4-
month (112 days) period following the date of ﬁrst visit (Table 1).
Eighty-seven patients were included in the comparator group,
representing all eligible patients on the respiratory nurse list of
Queen Elizabeth University Hospital on 5th March 2015. All 87
patients in the comparator group had baseline exacerbation data
collected from the 4-month period leading up to 21st August
2015, and follow-up exacerbations data extracted from the 4-
month period from 1st November 2015–28th February 2016.
Forty-nine (57%) of patients in the intervention group seen for the
ﬁrst time from July 2015 through February 2016, had follow-up
months that overlapped with the period covered in follow-up of
patients in the comparator group (Table 1).
Figure 1 describes patient ﬂow through the study.
In the intervention group, following the initial visit, nine
patients did not have any subsequent visits: the pharmacist did
not identify a need to follow-up ﬁve patients; one patient was
hospitalised; one patient was lost to follow-up and two patients
died. The remaining 77/86 (90%) received subsequent visits: the
median number of follow-up contacts per patient was 3 (range 1
to 10) and the median duration of intervention was 16 weeks (3 to
44 weeks). Duration of domiciliary visits averaged 30min (10 to
90min) and the approximate duration of weekly discussions
between consultant and pharmacist was 1 h. On average, the hour
spent with the consultant per week enabled discussion of four or
ﬁve patients.
Table 2 shows demographic and clinical variables at baseline.
The majority of patients (92.8% in the intervention group; 89.3%
in the comparator group) had moderate, severe, or very severe
COPD, with 80–90% MRC score 4 or 5. Patients in both groups
were predominantly female and lived in areas of high
Table 1. Intervention group: months included in exacerbations
Month No. of patients n= 86 Months includeda in baseline (exacerbations) Months includeda in follow-up (exacerbations)
March 2015 13 Nova, Dec, Jan, Feb, Mara Marcha, Apr, May, Jun, Jula
Apr 2015 10 Deca, Jan, Feb, Mar, Apra Apra, May, Jun, Jul, Auga
May 2015 6 Jana, Feb, Mar, Apr, Maya Maya, Jun, Jul, Aug, Sepa
Jun 2015 8 Feba, Mar, Apr, May, Juna Juna, July, Aug, Sep, Octa
Jul 2015 2 Marcha, Apr, May, Jun, Jula Jula, Aug, Sep, Oct, Nova
Aug 2015b 12 Apra, May, Jun, Jul, Auga Auga, Sep, Oct, Nov, Deca
Sep 2015 9 Maya, Jun, Jul, Aug, Sepa Sepa, Oct, Nov, Dec, Jana
Oct 2015 7 Juna, July, Aug, Sep, Octa Octa, Nov, Dec, Jan, Feba
Nov 2015 5 Jula, Aug, Sep, Oct, Nova Nova, Dec, Jan, Feb, Mara
Dec 2015 4 Auga, Sep, Oct, Nov, Deca Deca, Jan, Feb, Mar, Apra
Jan 2016 6 Sepa, Oct, Nov, Dec, Jana Jana, Feb, Mar, Apr, Maya
Feb 2016 4 Octa, Nov, Dec, Jan, Feba Feba, Mar, Apr, May, Juna
aPart month
bBaseline and follow-up data collection in comparator group
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socioeconomic deprivation. Despite being younger and having
fewer co-morbidities, there were statistically signiﬁcant differences
in the distribution of FEV1 staging between intervention and usual
care groups with fewer patients in the intervention group having
mild FEV1 readings, and more with readings assigned as ‘very
severe’. More patients in the intervention group had exacerbations
in the 4-month period prior to inclusion in the study, however,
exacerbations per patient year were balanced. There were fewer
non-respiratory co-morbidities in the intervention group although
there were a median of seven repeat prescriptions for non-
respiratory causes. Hospitalisations (proportion of patients hospi-
talised; median number of admissions per patient and days in
hospital) were comparable between groups. Patients in the
intervention group were almost twice as likely to have attended
a multidisciplinary out-patient appointment; the median number
of attendances per patient was three times that of patients in the
comparator group. Table 3 describes dispensed respiratory
medicines at baseline and follow-up in both the groups: 4-
months of follow-up repeat (maintenance) respiratory medicines
dispensed in the period November 2015 to February 2016 for
patients in the comparator group and 4 months after the ﬁrst
patient visit, in the intervention group. Eight patients who died
during this 4-month period (four patients in the intervention
group and four patients in the comparator group) were not
included in maintenance prescribing data collection at follow-up.
Greater numbers of patients in the intervention group were
receiving maintenance pharmacotherapy for COPD and related
respiratory problems: inhaled corticosteroid (ICS)/LABA; mucoly-
tics; antihistamines, leukotriene receptor antagonist (LRAs), and
notably, antibiotics and prednisolone, with a resulting median of
six respiratory medicines compared with four in the comparator
group. Table 4 describes changes introduced by the pharmacist,
after consulting with patients in the intervention group. The
changes described in Table 4 were collected by the researcher
accessing each patient’s electronic clinical record or by contacting
the patient’s GP. Alterations to pharmacotherapy were common
and wide-ranging, including respiratory and non-respiratory
conditions. Most changes introduced by the pharmacist involved
medicines: increase/decrease doses; start/stop; from one drug
type to another within the same class; starting a new medicine or
addressing poor inhalation technique (half of those receiving
intervention, although only 8% subsequently changed their
inhaler device). At least 72% of patients received at least one
change to their medicines with the most common being dose
changes followed by alteration of one prescribed drug to another.
The pharmacist referred over half (46 (53.5%) of patients to health
services in response to identiﬁed problems with co-morbid
conditions. A quarter of referrals involved expediting respiratory
out-patient clinic appointments, as the pharmacist responded to
the patient showing signs and symptoms of clinical deterioration.
Figure 2 shows changes in repeat dispensing for both groups
from baseline to follow-up.
There were notable increases in the use of the following
respiratory medicines suggesting a move towards more targeted
treatment in the comparator group: ICS/LABA (from 71.3% to
81.4%); mucolytic (from 43.7% to 51.7%); prednisolone (from 6.9%
to 16.1%); inhaled saline (from 6.9% to 18.4%); benzodiazepine
(12.6% to 24.1%); and opioids (16.1% to 26.4%) together
suggesting progression towards end stage COPD. Antihistamine
and LRA prescribing, which was higher in the intervention group
at baseline, increased further, from 19.8% to 24.4% and from
25.6% to 30.2%, respectively. Corresponding proportions of
patients receiving LRAs and antihistamines decreased in the
comparator group from baseline to follow-up (5.7% to 4.6% and
from 9.2% to 8%, respectively). Maintenance antibiotic prescribing
remained stable (and statistically signiﬁcantly different) over time
in both the groups.
Table 5 compares exacerbations (primary endpoint) and
respiratory hospitalisations (secondary outcomes) at follow-up
and Fig. 3 shows a graphical description of the primary and
secondary outcomes.
For hospitalisations and clinic visits, the mean duration of
follow-up in the intervention group was 312.9 days (SD 79.5) and
in the comparator group was 333.5 days (SD 68.0). Fewer patients
in the intervention group had respiratory exacerbations and there
were fewer exacerbations per patient year. This appeared to be
due to a decrease in the intervention group over time (from 95.3%
of patients at baseline to 63.5% of patients at follow-up), rather
than due to an increase from baseline to follow-up in the
comparator group where 83.9% at baseline increased to 86.2% at
follow-up. Hospitalisations for respiratory reasons remained stable
in the usual care group over time. Respiratory hospitalisations
(patients with event, days in hospital and number of admissions
per patient year) increased in the usual care group between
baseline and follow-up, with a resulting increase in costs.
Table 6 shows attendance at respiratory clinic, and RSN
attendances during the period of follow-up. Patients in the
intervention group had more frequent visits to the respiratory
clinic, as expected, as a result of the pharmacist intervention,
which included early identiﬁcation of symptom deterioration and
rapid access to specialist consultant led respiratory clinics. The
number of respiratory specialist nurse home visits increased over
time in both groups, with the greater increase in the comparator
group (from 36 (41.4%) of patients at baseline, to 84 (97%) at
follow-up).
Queen Elizabeth 
University 
Hospital COPD 
clinic 
n = 87 
Intervention 
group 
n = 88 records 
accessed for 
baseline data 
collection 
Comparator 
group 
n = 87 records 
accessed for 
baseline data 
collection
Declined (n = 2)
Comparator 
group 
n = 87 received 
usual care
Intervention 
group 
n = 86 received 
domiciliary visits
Intervention 
group 
Follow up data 
collection n = 86
Comparator 
group 
Follow up data 
collection n = 87
New Victoria 
Hospital COPD 
clinic  
n = 88 invited 
Intervention 
group 
n = 88 patients 
contacted and 
offered home 
visits
Fig. 1 Flow of participants through the study
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Summing the cost of respiratory hospitalisations; clinic atten-
dances; and RSN visits; together with the NHS salary cost of the
pharmacist (£17,215); and adding the cost of consultant time
(based on 1 h per week: £2000), overall there was a mean net
saving of £2205 (£25 per patient per year) in the intervention
group. There were no excess deaths during follow-up in either
group.
DISCUSSION
Main ﬁndings
A majority of patients accepted pharmacist input, which included
multiple, wide-ranging changes to individual patients’ respiratory
and non-respiratory medicines, and onward referral. Modest,
statistically signiﬁcant reductions in respiratory exacerbations,
respiratory hospitalisations, and respiratory nurse home visits were
observed after introducing the pharmacist intervention, in
comparison with a non-randomised control group, with an
increased frequency of attendances at consultant respiratory
physician clinic. The intervention may have been cost saving,
based on costs of staff time, clinic attendance, and hospitalisation.
Strengths and weaknesses
As far as we are aware, pharmacist home visits for patients with
COPD, where the pharmacist assesses and addresses the manage-
ment of COPD and multiple morbidities, has not previously been
investigated. The pharmacist collaborated with the patient’s
Table 2. Baseline characteristics of patients
Characteristica Intervention
group n= 88
Comparator
group n= 87
p-value
Demographics
Mean age, years (SD) 67.9 (9.8) 72.1 (9.4) 0.005
Gender, % female 67.1% 66.7% 0.958
Ethnicity (% white
British)
88 (100%) 87 (100%) 1.00
BMI (kg/m2; SD)b 25.5 (6.1) 26.3 (6.8) 0.430
Socioeconomic deprivationc
1 (most deprived) 45 (52.9%) 41 (47.1%) 0.086
2 16 (18.8%) 19 (21.8%)
3 4 (4.7%) 13 (14.9%)
4 7 (8.2%) 8 (9.2%)
5 (least deprived) 13 (15.3%) 6 (6.9%)
Clinical
Smoking (patient
reported)
Never smoked 2 (2.3%) 1 (1.2%) 0.675
Current smoker 23 (26.1%) 27 (31.0%)
Ex-smoker 63 (71.6%) 59 (67.8%)
% predicted FEV1 (mean
+/− SD)
48.5 (18.3) 52.5 (19.3) 0.194
FEV1 Stage
h
Mild (≥80%
predicted)
6 (7.1%) 8 (10.7%) 0.088
Moderate (50–79%) 28 (33.3%) 27 (36.0%)
Severe (30–49%) 37 (44.0%) 37 (49.3%)
Very severe (<30%) 13 (15.5%) 3 (4.0%)
COPD assessment test
(CAT) (median (IQR)d
27 (22–31) – –
Long-term oxygen
therapy
28 (31.8%) 22 (25.3%) 0.339
Medical Research Council (MRC) scoree
1 0 (0%) 1 (1.4%) 0.070
2 3 (3.5%) 3 (4.4%)
3 6 (6.9%) 7 (10.1%)
4 33 (37.9%) 31 (45.0%)
5 45 (51.7%) 27 (39.0%)
Number of co-
morbidities (median (IQR)
3 (2–4) 4 (2–6) 0.008
Type of co-morbidity
Asthma 12 (14.0%) 11 (12.6%) 0.80
Other respiratory co-
morbidity (not COPD or
asthma)
20 (23.3%) 15 (17.2%) 0.32
Lung cancer 1 (1.2%) 5 (5.7%) 0.10
Any cancer 18 (20.9%) 15 (17.2%) 0.78
Occlusive vascular
disease
19 (22.1%) 25 (28.7%) 0.75
Cardiovascular disease 41 (47.7%) 51 (58.6%) 0.66
Gastrointestinal disease 27 (31.4%) 29 (33.3%) 0.63
Central Nervous System 31 (36.0%) 33 (37.9%) 0.91
Osteoporosis 14 (16.3%) 19 (21.8%) 0.48
Endocrine 26 (30.2%) 36 (41.4%) 0.37
Musculoskeletal 22 (25.6%) 29 (33.3%) 0.26
Other long-term
condition
19 (22.1%) 23 (26.4%) 0.33
Respiratory repeat
prescriptions (median
(IQR))
6 (5–8) 4 (3–5) <0.001
Non-respiratory
repeat prescriptions
(median (IQR))
7 (4–10) 7 (4–10) 0.920
Table 2 continued
Characteristica Intervention
group n= 88
Comparator
group n= 87
p-value
Exacerbationsf,c
Patients with event 81 (95.3) 73 (83.9) 0.015
Exacerbations per
patient year (median, IQR)
4 (2–7) 4 (1–6) 0.199
Respiratory hospitalisationsg
Patients with event 42 (48.8) 46 (52.9) 0.595
Respiratory admissions
per patient year (median
IQR)
1 (0–2) 1 (0–2) 0.568
Days in hospital per
patient year (median (IQR)
0.00 (0–18.0) 1.00 (0–11.0) 0.530
Cost per patient year
(median, IQR)
0.00 (0–£49010) £2926 (0–£33649) 0.787
Respiratory clinic attendanceg
Patients with event 85 (98.8) 50 (57.5) <0.001
Clinic attendance per
patient year
3 (2–4) 1 (0–2) <0.001
Costi median (IQR) £711 (£474–£948) £237 (0–£474) <0.001
Respiratory Specialist Nurse home visitg
Patients with event 34 (39.5%) 36 (41.4%) 0.805
Costi median (IQR) 0 (0–£49) 0 (0–£49) 0.780
an% unless otherwise stated
Missing data:
bIntervention n= 1, comparator n= 8
cIntervention n= 3
dInterventionn= 1
eIntervention n= 1, comparator n= 18
fData from 4 month period prior to ﬁrst consultation in intervention group,
and four months before 24th August 2015, in the comparator group
gIn year prior to inclusion in the study
hIntervention n = 4, comparator = 12
iper year
A non-randomised controlled pilot study of clinical pharmacist. . .
V Hunt et al.
4
npj Primary Care Respiratory Medicine (2018)  38 Published in partnership with Primary Care Respiratory Society UK
consultant physician, and together they instigated, co-ordinated,
implemented, and followed up individualised action plans, in line
with recommended evidence.33 The intervention was delivered as
planned, to patients who were already receiving care from a
multidisciplinary primary and secondary care team, typical of
those within the NHS in the UK. The clinical pharmacist received
no speciﬁc additional respiratory therapeutics training prior to
visiting patients, suggesting the intervention could be implemen-
ted more widely, at no additional cost, by clinical pharmacists who
are established in general practices across the UK,20 but not
targeting patients with COPD who live at home. The intervention
had a theoretical underpinning—aiming to improve disease
speciﬁc self care and prescribing for respiratory and non-
respiratory conditions—and onward referral, all of which are
important to help prevent exacerbations in patients with COPD
living in the community.
The extent of the decrease in exacerbations in the intervention
group was marked, as was the increase in exacerbations per
patient year in the comparator group over time. Exacerbations
and hospitalisations reduced over time and relative to the
comparator group. Consultant respiratory clinic attendance
increased and together with the increase in prescribing of
medicines known to improve outcomes, suggests a signal of
beneﬁt, which may be due to pharmacist led case management,
although further work is required to establish causality due to
limitations of the methods. Outcome data collection using linkage
of each patient’s unique health number to the patient’s current
health records, minimised errors, and reduced the cost and risk of
bias from selective outcome reporting. A similar, but less accurate
approach, using algorithms to match patients’ demographic data
to their health records, has been compared favourably with
traditional clinical trial methods.34,35 Our estimation of costs did
not include the cost of medicines, because of limitations in time
available to the researcher. Given the importance of medicines in
the study, and the cost of some of the medicines prescribed, e.g.,
leukotriene receptor antagonists and combination inhalers, future
work should include identiﬁcation and measurement of medicines
costs.
Several methodological issues biased the results. The ﬁndings
should be treated with caution given the signiﬁcant risk of bias
arising from the lack of a randomised control group, and the
absence of a power calculation to inform sample size and duration
of follow-up. There were statistically signiﬁcant imbalances
between intervention and usual care groups, in key variables at
baseline (younger age; fewer co-morbidities; more antibiotic,
steroid, mucolytic, antihistamine, and leukotriene receptor
antagonist prescribing) all of which might be expected to
confound the results by reducing exacerbations in the interven-
tion group. However, exacerbations were more common in the
intervention group than in the comparator group at baseline;
which may be due to more patients in the intervention group
having baseline data collected over winter months (when
exacerbations are more common), compared with the comparator
group where baseline data were collected for all patients from
April to August. Similarly, the months of follow-up differed
between intervention and comparator groups (more summer
months included in the intervention group), which may also have
biased the ﬁnding that exacerbation rates improved in the
intervention group relative to the comparator group. Hospitalisa-
tions (number and duration) were collected over the year before
and after the intervention in the active group, and 1 year before
and after the mid point date in the comparator group, therefore,
were not subject to the bias due to seasonal variation seen in
exacerbations.
Lack of assessment of symptoms, knowledge about symptoms
and management or adherence in both groups may be
considered another weakness, and require to be addressed in
subsequent work.
Table 3. Respiratory repeat (maintenance) prescribing at baseline and follow-up
Baselinea Follow-up
Intervention group
n= 88
Comparator group
n= 87
p- value Intervention
(n= 82)
Comparator
(n= 83)
p-value
Short acting beta2 agonist (SABA) 73 (84.9%) 76 (87.4%) 0.638 79 (90.8%) 77 (89.5%) 0.78
Short acting muscarinic antagonist
(SAMA)
3 (3.5%) 2 (2.3%) 0.641 6 (7.0%) 1 (1.1%) 0.05
Long acting muscarinic antagonist (LAMA) 72 (83.7%) 68 (78.2%) 0.352 72 (82.8%) 71 (82.6%) 0.97
Inhaled corticosteroid (ICS)/long acting
beta-adrenoreceptor agonist (LABA)
75 (87.2%) 62 (71.3) 0.010 74 (85.1%) 70 (81.4%) 0.51
LAMA/LABA 0 (0%) 1 (1.2%) 0.217 1 (1.2%) 2 (2.3%) 0.77
LABA 2 (2.3%) 3 (3.5%) 0.659 1 (1.2%) 1 (1.1%) 0.57
ICS 4 (4.6%) 6 (6.9%) 0.527 4 (4.7%) 1 (1.1%) 0.16
Mucolytic 59 (68.6%) 38 (43.7%) 0.001 62 (72.1%) 45 (51.7%) 0.006
Antihistamine 22 (25.6%) 8 (9.2%) 0.004 26 (30.2%) 7 (8.0%) <0.001
Leukotriene receptor antagonist (LRA) 17 (19.8%) 5 (5.7%) 0.006 21 (24.4%) 4 (4.6%) <0.001
Theophylline 20 (23.3%) 12 (13.8%) 0.109 18 (20.9%) 15 (17.2%) 0.54
Antibiotic (maintenance) 58 (67.4%) 25 (28.7%) <0.001 60 (69.8%) 26 (29.9%) <0.001
Prednisolone (maintenance) 29 (33.7%) 6 (6.9%) <0.001 32 (37.2%) 14 (16.1%) 0.002
Antifungal 3 (3.5%) 0 (0.0%) 0.079 2 (2.3%) 0 (0%) 0.005
Saline (inhaled) 11 (12.8%) 6 (6.9%) 0.193 15 (17.4%) 16 (18.4%) 0.67
Benzodiazepine 15 (17.4%) 11 (12.6%) 0.377 22 (25.6%) 21 (24.1%) 0.83
Opioid (oral) 11 (12.8%) 14 (16.1%) 0.537 16 (18.6%) 23 (26.4%) 0.218
aAt ﬁrst consultation
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Strengths and weaknesses in comparison to other studies
We included a modest number of patients, and a comparable
duration of follow-up, to previous evaluations of pharmacist care
of patients with COPD17 and controlled trials of complex
interventions for COPD in general.14,15,18,36 In comparison with
other studies, participants were more likely to be female; older;
from more socioeconomically deprived areas; have more co-
morbid conditions and polypharmacy, and more advanced
respiratory symptoms.17,18 Our intervention breaks new ground,
by focussing on COPD while also addressing polypharmacy and
multiple morbidities, and involvement of a GP-based clinical
pharmacist rather than a community pharmacist.37 Participating
patients had more than double the number of prescribed
medicines than previously described in a descriptive study of 78
patients with COPD,38 suggesting a greater associated medication
burden39 and the utility of clinical pharmacist input to review and
modify respiratory and non-respiratory medicines. A wider range
of pharmacist interventions were employed, e.g., rapid referral
directly into the respiratory clinic, initiation of any medicine for
any condition, compared with previous pharmacist interventions
that have tended to focus on COPD education, adherence, and
inhaler technique.14–18 The link with a consultant respiratory
physician contributed to patients receiving appropriate and rapid
changes to their medicines and the pharmacist’s access to general
practices, enabled changes to repeat and acute prescribing
through conventional channels. The current study included a
comparator group, as opposed to a pre-and post-study design
using only an intervention group.25,40 Our study agrees with other
studies where pharmacist intervention reduced respiratory
hospitalisation17 and exacerbations14 although our outcomes
were achieved through a different intervention, and in a cohort
with multiple co-morbidities, which negatively inﬂuences disease
expression and survival.41,42
In pragmatic trials involving complex intervention testing,
intervention ﬁdelity is an important consideration because the
effect of the intervention depends on whether all elements are
implemented as planned.43 The number and duration of treat-
ment sessions delivered by the pharmacist varied according to the
pharmacist’s and patient’s perceptions of length of time needed
to assess and address relevant issues. The median of four per
Table 4. Prescribing and other changes due to pharmacist
intervention
N (%) patients
n= 86
N (%) of changes
n= 516
Medication changesa
Dose 62 (72.1) 153 (29.6)
Drug 45 (52.3) 80 (15.5)
New drug initiated 39 (45.3) 70 (13.6)
Existing drug discontinued 46 (53.5) 69 (13.4)
Inhaler technique corrected
through demonstration
39 (45.3) 52 (10.1)
Oxygen prescription changed 9 (10.5) 9 (1.7)
Restart previously prescribed
drug
28 (32.5) 36 (7.0)
Formulation 16 (18.6) 17 (3.3)
Repeat prescription
/community pharmacy re-
ordering
9 (10.5) 11 (2.1)
Change inhaler device 7 (8.1) 7 (1.4)
Dose timing 4 (4.6) 4 (0.8)
Adherence issue 3 (3.5) 4 (0.8)
Adverse drug reaction 2 (2.3) 2 (0.4)
Duration of treatment 2 (2.3) 2 (0.4)
Referrals n= 127
Dual energy X-ray
absorptiometry
33 (38.4) 33 (26.0)
Health services (non-
respiratory)b
46 (53.5) 57 (44.8)
Respiratory out-patient clinic 21 (24.4) 27 (21.2)
Investigations, e.g., ECG, blood
gasses, CT scan
10 (11.6) 10 (7.8)
aRespiratory medicines and others, e.g., azithromycin, lanzoprazole,
residronate, morphine, nortryptiline. Itraconazole, gabapentin, statin
bFor example: immunology, pulmonary rehabilitation, pain clinic, cardiol-
ogy, diabetic foot check, physiotherapy.
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Fig. 2 Changes in respiratory repeat (maintenance) dispensing for intervention and comparator groups from baseline to follow-up
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patient is considerably less than the mean of 13.7 cited in
systematic reviews of previous work.18 The duration of each
patient contact could also be important in building trust and
developing a therapeutic relationship; the pharmacist spent on
average, 30 min with patients in their homes at each visit.
Improved outcomes are likely to be a function of the skills and
knowledge of the pharmacist, rapid input from the consultant
physician.
Table 5. Changes in primary and secondary outcomes at follow-up
Outcome Intervention n= 86 Comparator group n= 87 p-value
Exacerbationsa
Patients with event 54 (63.5%) 75 (86.2%) 0.001
Exacerbations/patient year (median, IQR) 2 (0–6) 6 (4–10) <0.001
Respiratory hospitalisations
Patients with event 39 (45.3%) 66 (76.7%) <0.001
Days in hospital/patient year (median, IQR) 0 (0–10.29) 9.48 (0–30.02) <0.001
Respiratory admissions/patient year (median (IQR) 0 (0–2.1) 1.6 (0–3.6) <0.001
Cost per year (mean (SD)) £32390 (£77607) £53946 (£66748) –
n% unless otherwise stated
aMissing values:n= 1
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Fig. 3 Changes in primary and secondary outcomes between baseline and follow-up for intervention and comparator groups
Table 6. Clinic, respiratory specialist nurse, and mortality during follow-up
Respiratory clinic attendance Intervention n= 86 Comparator group n= 87 p-value
Patients with event (median, IQR) 70 (81.4) 50 (57.5) <0.001
Event rate/patient year (median, IQR) 2.1 (1.0–3.3) 1.6 (0–3.2) 0.014
Cost per year (mean, SD) £460 (£332) £291 (£312) −
Respiratory specialist nurse home visit
Patients with event 44 (51%) 84 (97%) <0.001
Event/patient (median (IQR)) 1 (0–2) 3 (1–4) <0.001
Cost (mean (SD) £25 (£19) £48 (£46) −
Death from any cause
Patients with event 14 (16.3%) 19 (21.8%) 0.53
A non-randomised controlled pilot study of clinical pharmacist. . .
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Meaning of the study
Pharmacotherapy is one of the main approaches in the manage-
ment of COPD with appropriate treatments reducing the
frequency and severity of exacerbations,2 but polypharmacy is
burdensome and associated with patients hospitalised with acute
exacerbations.44 It is plausible that repeated pharmacist interven-
tion to ensure optimal pharmacotherapy and minimise adverse
effects, with a direct link to a consultant respiratory physician, and
the patient’s GP, may lead to improved outcomes. Confounding
these ﬁndings are a lack of a randomised controlled group, and
different periods for follow-up data collection between groups, all
of which require to be addressed before attributing causation.
Our a-priori hypothesis was that a novel model of care involving
collaboration between pharmacist and consultant respiratory
physician could improve outcomes. While all patients (including
those with COPD) are registered with a GP, we targeted a subset
of patients with severe and disabling COPD, who were already
receiving secondary care input from consultant respiratory
physicians at the hospital outpatient respiratory clinic. We,
therefore, chose to try to enhance the existing care process
between consultant respiratory physician and patient through
pharmacist intervention, rather than focus on the care process
between patient and GP. Our team has previously tried to
enhance the care process between patient and GP, through
pharmacist intervention in a previous study examining outcomes
in patients with heart failure due to LVSD.23 This approach had
limited success (albeit for a different group of patients) and the
learning encouraged us to target a sicker group of patients by
supporting consultants directly.
Our intervention maintained the notion of community care, by
ensuring all changes agreed between pharmacist, consultant
respiratory physician, and patient were communicated to the
patient’s GP. The intervention was in addition to community care;
it did not replace any aspect of community care.
If subsequently proven to be effective and cost effective in a
pragmatic randomised controlled trial, the current ﬁscal climate
and a shortage of GPs would make clinical pharmacist home visits
an attractive proposition,45 in COPD where tailored pharma-
cotherapy and non-pharmacologic interventions, e.g., pulmonary
rehabilitation, are important to maintain health.7,46 A novel,
pharmacist, and respiratory physician collaborative intervention
is feasible and may improve outcomes, and merits investigation in
a randomised controlled trial.
METHODS
We examined the effect of pharmacist intervention in a non-randomised
controlled pilot intervention study with a contemporaneous comparator
group.
Setting
NHS Greater Glasgow and Clyde (GG&C) Health Board is Europe’s largest
health board, providing healthcare for approximately 1.15 million patients
in the West of Scotland. Primary care medical services are provided free of
charge through 240 general practices. General practices are independent
contractors providing medical services for patients within the Health
Board. Each patient is registered with one general practice where they can
be seen by any of the GPs within the practice. Patients rarely chose to
change practice other than for practical reasons, e.g., due to moving house.
Practices have employed, permanent staff, e.g., practice nurses, and may
also have visiting, temporary staff, e.g., podiatrists, who are employed by
the Health Board. For the duration of the study, other than the pharmacist
delivering the intervention described in this study, no respiratory specialist
pharmacists were employed by or visited the practices of patients involved
in the study. Secondary care services are provided through 35 hospitals,
with seven specialist respiratory nurse (RSN) teams. Patients with COPD
receive specialist care from consultant respiratory physicians and RSNs, in
out-patient COPD clinics or during hospitalisation for respiratory reasons.
In the immediate post hospital discharge period, RSNs visit patients at
home.
Inclusion criteria
Both groups were managed in the same health board, and the same
regular care processes were in place in all Glasgow hospitals. The
intervention group out-patient facility ran a COPD specialist clinic from
which patients were recruited for the pharmacist intervention. No similar
pharmacist service was run at the comparator group out-patient facility. To
be eligible for inclusion patients had to have: spirometrically conﬁrmed
COPD; their name on the clinic list of the specialist respiratory team of the
New Victoria or Queen Elizabeth University Hospital during March 2015;
and live at home. The intervention group was identiﬁed from the New
Victoria respiratory clinic list cluster and the comparator group were
identiﬁed from the Queen Elizabeth University Hospital RSN cluster, to
avoid contamination in this non-randomised pilot study. Both hospitals
were located within NHS Greater Glasgow and Clyde and all clinical staff
followed shared NHS GG&C guidelines for the management of COPD and
other conditions.
Pharmacist intervention
A general practice-based clinical pharmacist with an interest in respiratory
therapeutics, worked 3 days per week, collaborating with a specialist
respiratory physician, over 1 year. All patients were offered pharmacist
home visits. During this ﬁrst consultation, the pharmacist and the patient
decided, on the basis of the pharmacist’s assessment (Appendix I) and
professional judgement, whether there was merit in return visits to
introduce and follow-up changes.
After collecting demographic and symptoms scores, the pharmacist
discussed each of the patients’ medications, for each condition (respiratory
and non-respiratory), respiratory symptoms, exacerbation frequency, and
possible triggers were discussed and patients were encouraged to respond
promptly to the symptoms of an exacerbation by starting oral steroids;
antibiotic therapy (when sputum was purulent), and increasing the dose of
inhaled therapy, in line with best practice.7 Positive reinforcement of the
importance of medicines and symptom awareness was given at each visit.
The patient’s non-respiratory medicines and co-morbid conditions were
discussed and where appropriate, the pharmacist made recommendations
for change to the patient’s GP using a previously established communica-
tion pathway, which results in GP acceptance and pharmacist implementa-
tion of the changes.23 Patients were prospectively screened for risk of
osteoporosis using FRAX score and referred for bone mineral density
dependant on this result.
The pharmacist and patient agreed an individualised respiratory
management plan and medicines changes or onward referrals were
implemented by the pharmacist with consultant respiratory physician
input to respiratory matters. Scheduled follow-up visit dates were agreed,
and the pharmacist implemented and co-ordinated communication of all
of the changes, by contacting all relevant stakeholders: the patient’s GP,
community pharmacist and any services to which the patient was referred,
e.g., dual energy X-ray absorptiometry (DEXA); smoking cessation support;
or referral for pulmonary rehabilitation. Speciﬁc therapeutic approaches
included targeted or long-term antibiotics in those found to have bacterial
colonisation; high-dose inhaled corticosteroids, antihistamines, or leuko-
triene receptor antagonists in patients with features suggesting COPD with
asthma; treatment of fungal infection; or palliative care. Patients were
asked if and how they took their medicines, and individualised support
provided if necessary, e.g., simpliﬁcation of dose regimens therefore,
assessing and addressing adherence was not a common feature of the
intervention received by each patient, whereas, positive reinforcement of
the importance of speciﬁc parts of the patient’s therapeutic regimen, were
covered at each visit. Inhaler technique was corrected where necessary by
demonstration using placebos.
Usual care
All patients (including those who received the pharmacist’s intervention)
continued to receive usual care from their GP and multidisciplinary
specialist respiratory team (consultant respiratory physician and RSN).
Comparator group patients received no clinical pharmacist input
throughout the study period.
A non-randomised controlled pilot study of clinical pharmacist. . .
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Consent
The NHS Greater Glasgow and Clyde Respiratory Managed Clinical Network
and NHS Greater Glasgow and Clyde Ethics screener approved the project
as a new service evaluation; as such, written consent was not required or
requested from participants.
Measures
Data collection. In Scotland, and the rest of the UK, the patient’s GP has
an electronic record containing all of the patient’s clinical information,
including details of secondary care contacts and prescribed medicines.
Data on dispensed medicines are not available within GP records, because
data on dispensed medicines are captured in community pharmacies,
where the medicines are dispensed to patients on receipt of a prescription.
Data on dispensed medicines captured in community pharmacies are sent
electronically (automatically linked to the patient’s CHI number (a ten digit
unique identiﬁer based on date of birth, assigned to each patient, by NHS
Scotland), to a central electronic store (Prescribing Information System, PIS,
part of Information Services Division, NHS Scotland) and made available to
NHS Staff on demand, e.g., for service evaluation. While the information
contained in GP records can only be accessed in the practice and not
remotely, some of the data contained in the GP records (e.g., hospitalisa-
tions; out-patient clinic attendance, and specialist respiratory nurse
domiciliary visits) can also be accessed remotely through a clinical record
system called Clinical Portal. Again, these data are accessible for individual
patients, using the patient’s CHI number. In the study, we made use of all
of these systems for data collection at baseline and follow-up.
Baseline demographic and clinical data were extracted from hospital
and GP-based electronic case records. COPD assessment test (CAT) scores
were only collected in the Intervention group, by the pharmacist, at the
ﬁrst consultation. Routine clinical data sources used to access information
on comparator group patients did not include CAT scores.
All medicines were obtained by the patient from their community
pharmacy. Given the unreliability of questionnaires as measures of
assessing adherence,47 we used community pharmacy dispensed pre-
scribing records as our measure of adherence. Dispensed prescriptions
(baseline and follow-up) were collected using PIS, which captured drug
names; doses; dispensing date; quantities; and formulations dispensed in
community pharmacies in Scotland.48 Two types of prescription can be
ascertained from dispensed data: repeat (maintenance, where the PIS
record shows the patient has collected enough of their medicine to enable
daily dosing) and acute (episodic, short courses of medicines including
treatment for exacerbations, inferred from the date and quantity of
collected medicine on the PIS record). A supply of medicine was
categorised as repeat (maintenance) if the patient’s linked electronic
dispensing record showed at least 4 consecutive months of enough
dispensed medicines to enable daily dosing. The supply of medicine was
categorised as acute when the medicine was dispensed as one or more
short courses because this meant the patient did not have sufﬁcient
supplies of medicine to take it every day over a 4-month period. Given the
importance of primary care management of COPD to prevent exacerba-
tions requiring hospitalisation, we selected the number of primary care
exacerbations as our a-priori primary outcome. An exacerbation included
short courses of antibiotics (5–14 day course of penicillin, macrolide, or
doxycycline either as a change to antibiotic class in patients already
receiving maintenance antibiotics, or initiation in a patient not previously
receiving one) with or without concomitant high-dose steroid (5–14 day
course of prednisolone at a dose greater than 10mg or a higher than
maintenance dose in patients already receiving maintenance steroids) or
high-dose steroid alone.7
In the intervention group, exacerbations at baseline were obtained by
extracting PIS data over the 4-month period prior to each patient’s ﬁrst
contact with the pharmacist. In the comparator group, PIS exacerbation
data were also extracted over a 4-month period—prior to the 24th August
2015 (the date of the mid point of consultations in the intervention group).
Follow-up data on the number of exacerbations were collected over the
4-month period November 2015 to February 2016 for patients in the
comparator group, and in the 4-month period from the date of ﬁrst
consultation for patients in the intervention group.
Hospitalisations, multidisciplinary out-patient clinic attendance and
nurse domiciliary visits, were collected from the electronic clinical
management system used to record the date and cause of hospital
admissions (Clinical Portal). At baseline, these were collected over 1 year
prior to the date of ﬁrst consultation in the intervention group, and from
24th August 2014 to 24th August 2015 in the usual care group. At follow-
up, hospitalisations, multidisciplinary respiratory out-patient attendances
and respiratory nurse specialist home visits were collected over 1 year for
all patients: 1 year from the date of each ﬁrst consultation in patients in the
intervention group, and 1 year from the 24th August 2015 for patients in
the comparator group. In both groups, censoring took place on the date of
death.
Costs. The cost of admissions, multidisciplinary out-patient clinic visits,
and respiratory specialist nurse home visits were obtained from ISD
Scotland, and summed over the year before and year after each patient’s
ﬁnal visit (in the intervention group) or in the year before and year after
the index date of 24th August 2015 (in usual care). Costs were obtained by
multiplying the net cost of an inpatient bed day, out-patient attendance or
RSN, by the number of days in hospital or number of clinic attendances or
the number of specialist nurse visits, respectively. Pharmacist and RSN
costs were taken from Agenda for Change pay scales and consultant
physician time were obtained directly from NHS GG&C. Medicines costs
were not included in our analysis.
Statistical analysis
Continuous variables are described using mean (SD), median, inter-quartile
range (IQR), and range as appropriate. Categorical variables are described
using the number and percentage falling into each category reported, with
percentages calculated relative to the number of non-missing. The number
missing was reported for all variables. Differences between the pharmacist
intervention and comparator group in terms of the observed variables
were tested using two sample t-tests or Mann–Whitney tests for
continuous data, depending on the distributions. Categorical variables
were analysed using Chi-squared tests or Fisher’s tests as appropriate. For
all analyses, a p-value < 0.05 was considered to indicate statistical
signiﬁcance; p-values are shown for reference. Statistical analyses were
carried out using MINITAB version 16.
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